Does Humana Cover Zepbound for Weight Loss?

What Zepbound Is and Why Coverage Is Complicated

Zepbound is a once-weekly injectable tirzepatide approved by the FDA on November 8, 2023, specifically for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension or type 2 diabetes [1]. It is the same molecule as Mounjaro, which is approved for type 2 diabetes, but the Zepbound label targets obesity exclusively.

The complexity around coverage stems from a 2003 federal statute (Medicare Prescription Drug, Improvement, and Modernization Act) that explicitly excludes drugs used for weight loss from Medicare Part D formularies [2]. That statutory exclusion flows downstream to most Medicare Advantage Part D plans, including those administered by Humana. Commercial Humana plans are not bound by the same restriction, but employer groups and individual plan purchasers often choose benefit designs that omit obesity pharmacotherapy to control premiums.

SURMOUNT-1 (N=2,539) demonstrated that tirzepatide 15 mg produced a 20.9% mean reduction in body weight at 72 weeks versus 3.1% for placebo (P<0.001) [3]. A separate analysis published in NEJM showed that 36.2% of participants on the 15 mg dose lost at least 25% of body weight [3]. Those efficacy numbers have intensified patient demand, which in turn has made coverage disputes with insurers more frequent.

The American Gastroenterological Association's 2022 clinical practice guideline states: "Pharmacotherapy for obesity should be offered to adults with BMI ≥30 or ≥27 with comorbidities who have not achieved weight loss goals through lifestyle intervention alone." [4] Despite that clinical consensus, payer policies have not uniformly followed suit.

Humana Commercial Plans: Coverage at a Glance

On Humana commercial plans (employer-sponsored and individual/family), Zepbound coverage exists but is not guaranteed. Employers ultimately choose which drugs appear on their plan's formulary, so two people both insured through Humana may have completely different outcomes when they request Zepbound.

When coverage is present on a commercial plan, Zepbound typically sits at Tier 4 or Tier 5, the specialty tiers that carry the highest cost-sharing. At Tier 4, a member might owe 25 to 33% coinsurance after meeting a deductible, translating to $265, $350 per month out of pocket even with coverage. At Tier 5, coinsurance can reach 40 to 50%, which for a $1,059 list-price drug means $420, $530 per month.

Checking your specific plan formulary takes about two minutes. The Humana drug finder at humana.com accepts your plan ID and drug name and returns the current tier, any restrictions, and estimated cost-sharing. A formulary lookup on your Summary of Benefits and Coverage document will also indicate whether an obesity drug benefit exists at all before you invest time in a prior authorization [5].

The Obesity Medicine Association's 2023 position statement notes that "denial of coverage for anti-obesity medications is inconsistent with coverage of other chronic disease pharmacotherapy and contributes to worsening population health outcomes." [6] That framing is worth including in any appeal letter because it positions the denial as medically inconsistent, not merely inconvenient.

Humana Medicare Advantage and Part D: The Statutory Barrier

Most Humana Medicare Advantage plans do not cover Zepbound for weight loss. This is not a Humana policy preference; it reflects 42 U.S.C. §1395w-102(e)(2), the section of federal law that lists "agents used for anorexia, weight loss, or weight gain" among the excluded drug categories under Part D [2].

CMS issued guidance in April 2024 clarifying that plans may voluntarily add obesity medications as a supplemental benefit, but this is optional and most Humana MA plans had not widely adopted it as of mid-2025 [7]. A specific exception applies: if a Humana MA member has type 2 diabetes and the prescribing clinician writes for tirzepatide under the Mounjaro NDC code for diabetes management, Part D coverage may apply because the diabetes indication is not excluded [8]. That pathway requires a documented type 2 diabetes diagnosis. Using Mounjaro NDC codes for a patient without diabetes solely to obtain coverage is fraudulent billing.

For MA members denied coverage, the MAXIMUS Federal Services external appeal process is the statutory mechanism. MAXIMUS reviews are independent of Humana and must be completed within 72 hours for expedited requests or 30 days for standard requests per CMS regulations [9].

Prior Authorization Criteria for Zepbound on Humana Commercial Plans

Prior authorization for Zepbound on Humana commercial plans generally requires documentation of several clinical elements. Requirements vary by employer group, but the following criteria appear consistently across Humana PA policies reviewed by the HealthRX medical team.

Diagnosis and BMI documentation. The prescriber must supply a current BMI measurement. Most Humana PA forms accept BMI of 30 kg/m² or greater, or 27 kg/m² or greater with a documented comorbidity. Acceptable comorbidities typically include hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease [10].

Dietary and behavioral intervention. Humana usually requires evidence that the patient has attempted a structured diet and exercise program for at least three to six months without achieving clinically meaningful weight loss (commonly defined as <5% body weight reduction). Documentation from a registered dietitian, a primary care visit note, or a formal weight management program enrollment record all serve this purpose [11].

Contraindications screening. The PA form requires confirmation that the patient does not have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, per the FDA-approved Zepbound prescribing information [1].

Prescriber specialty. Humana does not restrict Zepbound prescribing to endocrinologists, but some employer plans add that layer. A primary care physician, internist, or any licensed prescriber with obesity management experience may submit the PA on most standard Humana commercial plans [12].

Baseline labs. HbA1c, fasting glucose, and a lipid panel are commonly requested to establish the cardiometabolic burden and to rule out existing undiagnosed type 2 diabetes (which would redirect the prescription to Mounjaro under a different benefit) [13].

Turnaround time for Humana commercial PA decisions runs 3 to 15 business days under standard review. Expedited review, available when a provider certifies that the standard timeline would seriously jeopardize health, must be completed within 72 hours [14].

Step Therapy Requirements Before Zepbound

Step therapy means the plan requires a patient to try and fail at least one lower-cost alternative before approving the requested medication. Humana applies step therapy on many commercial plans that cover Zepbound.

Step therapy for obesity medications at Humana most commonly requires a trial of one or more of the following agents: orlistat (Xenical/Alli), phentermine/topiramate extended-release (Qsymia), naltrexone/bupropion (Contrave), or liraglutide 3 mg (Saxenda) [15]. A trial period of 12 weeks is typical. The definition of "failure" generally means <5% body weight loss or intolerable adverse effects documented in the medical record.

If a patient has already tried one of these agents through a prior insurance plan or as a cash-pay prescription, that documented history often satisfies the step requirement. The prescriber must submit pharmacy dispensing records, prior plan EOB documents, or a detailed chart note describing the prior trial and its outcome [16].

Step therapy exceptions are available under many state laws. As of 2025, 28 states have enacted step therapy exception statutes requiring insurers to grant exceptions within specific timeframes when a clinician certifies that the required step drug is medically inappropriate, contraindicated, or previously failed [17]. Humana must comply with those state laws for fully-insured commercial plans. Self-funded employer plans are governed by ERISA and are largely exempt from state step therapy mandates, which is a meaningful distinction [18].

The American Association of Clinical Endocrinologists 2023 obesity guidelines recommend tirzepatide as a first-line pharmacotherapy option based on its efficacy profile, explicitly noting that step therapy to less-effective agents may delay appropriate treatment and worsen long-term outcomes [19].

How to Appeal a Humana Denial of Zepbound

A denial letter from Humana is not a final answer. Two out of every five insurer denials that reach formal external review are overturned, according to a 2023 KFF analysis of state external appeal data [20]. The appeal process has a defined structure, and following it precisely improves success rates.

Step 1: Internal Humana appeal (Level 1). File within the deadline stated in the denial letter, usually 180 calendar days for commercial plans. Submit a written appeal that includes the denial letter, the full medical record supporting the diagnosis and prior treatment history, a letter of medical necessity from the prescriber, and any peer-reviewed clinical evidence supporting Zepbound's use. Humana must respond to a standard internal appeal within 30 days for medical/drug benefits and within 72 hours for expedited appeals [21].

Step 2: Second-level internal appeal (Level 2). If the Level 1 appeal is denied, most Humana commercial plans allow a second internal review. Include any additional documentation obtained since Level 1, such as updated weight logs, new lab results, or a specialist's letter [22].

Step 3: External independent review. After exhausting internal appeals, the member may request an external independent review organization (IRO) review. The IRO's decision is binding on Humana under most state laws. Submit within 60 days of the final internal denial [23].

For Medicare Advantage denials. The MA appeals pathway differs: Level 1 is a Humana internal redetermination, Level 2 is a Qualified Independent Contractor (QIC) review, Level 3 is an ALJ hearing, Level 4 is a Medicare Appeals Council review, and Level 5 is federal district court. For standard drug denials, MAXIMUS Federal Services handles the QIC review and must issue a decision within 7 days for standard requests or 72 hours for expedited requests [9].

Key documentation for any Zepbound appeal: the SURMOUNT-1 trial data showing 20.9% weight loss at 72 weeks [3], the FDA-approved indication language from the Zepbound label [1], any applicable AGA or AACE guideline language supporting pharmacotherapy, and the patient's complete weight history.

The Eli Lilly Savings Card: Who Can Use It With Humana?

Eli Lilly's Zepbound savings card (LillyDirect) can reduce out-of-pocket costs to as low as $25 per month for eligible commercially insured patients [24]. The critical restriction: the savings card cannot be used by Medicare, Medicaid, or any other government program beneficiary. Federal law (the anti-kickback statute) bars manufacturer coupons from being used with federal payers [25].

For Humana commercial members who have coverage but face high cost-sharing at Tier 4 or 5, the savings card applies to the copay or coinsurance after insurance processes the claim. For Humana commercial members whose plan does not cover Zepbound at all, the card can be applied to a cash-pay transaction but the cash-pay list price of $1,059 per month applies before the card discount.

Humana Medicare Advantage members are categorically ineligible for the savings card. Their only manufacturer-sponsored option is the Lilly Insulin Value Program, which does not extend to Zepbound.

Compounded tirzepatide was available from 503B outsourcing facilities during the FDA shortage period. The FDA removed tirzepatide from the shortage list in January 2025, triggering enforcement action against compounders [26]. As of mid-2025, commercially manufactured Zepbound pens are the only legally available form, and compounded versions carry regulatory and safety risks that the HealthRX medical team advises against.

Clinical Rationale: Why Prescribers Push for Coverage

Tirzepatide's mechanism is distinct from older GLP-1 receptor agonists. It acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor, a combination that produces greater appetite suppression and metabolic improvement than GLP-1 agonism alone [27].

SURMOUNT-2 (N=938), published in The Lancet in 2023, studied participants with type 2 diabetes and obesity. Tirzepatide 15 mg produced 15.7% mean weight loss at 72 weeks versus 3.3% for placebo (P<0.001) [28]. The SELECT trial with semaglutide 2.4 mg (Wegovy, a GLP-1 comparator) showed a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease [29], and similar cardiovascular outcome data for tirzepatide are expected from the SURPASS-CVOT trial.

The FDA's prescribing information for Zepbound specifies that the drug is indicated as an adjunct to a reduced-calorie diet and increased physical activity [1]. That adjunct language is precisely what Humana PA forms reference when requiring documentation of diet and exercise attempts. Prescribers who frame their PA requests to mirror the FDA label language exactly report faster approvals in HealthRX's clinical network experience.

A 2024 analysis in JAMA Network Open (N=3,144) found that patients prescribed tirzepatide had a 38% lower rate of obesity-related emergency department visits over 12 months compared with matched controls on lifestyle intervention alone [30]. That finding supports the economic argument for coverage: the drug cost may be offset by reduced downstream utilization.

The Endocrine Society's 2023 clinical practice guideline on obesity recommends: "Clinicians should offer pharmacotherapy to adults with obesity as an adjunct to lifestyle intervention, with medication selection based on efficacy, safety profile, patient comorbidities, and access." [31]

Practical Steps to Maximize Your Chances of Approval

Getting Zepbound approved is a documentation exercise as much as a clinical one. The following sequence reflects patterns from successful PA submissions reviewed by the HealthRX clinical team.

First, confirm your plan covers obesity pharmacotherapy at all. Pull your Summary of Benefits or call Humana's pharmacy benefit number (on the back of your insurance card) and ask directly whether "anti-obesity medications" or "chronic weight management drugs" appear anywhere in the benefit structure. If they do not, a PA will be denied before any clinical criteria are assessed, and you should move directly to appeal or employer escalation [32].

Second, ask your prescriber to document BMI, at least one weight-related comorbidity, prior treatment attempts, current medications, and the absence of tirzepatide contraindications in a single comprehensive note. A fragmented chart slows the PA reviewer and increases denial risk.

Third, if step therapy is required and you have not yet tried a required agent, discuss with your prescriber whether any of the step drugs are appropriate for your clinical situation. Phentermine/topiramate is contraindicated in pregnancy and certain cardiovascular conditions; orlistat causes gastrointestinal adverse effects that many patients cannot tolerate. Documented contraindications or intolerances to step agents satisfy most Humana step therapy exception criteria [33].

Fourth, set a calendar reminder for the PA renewal. Humana commercial approvals for Zepbound typically run 12 months, after which the prescriber must submit evidence of ongoing clinical response (generally defined as at least 5% body weight loss from baseline) and continued medical necessity [34].

Patients who track their weight weekly and bring printed logs to follow-up visits give their prescribers the strongest possible renewal documentation. A 5% weight reduction from a 250-pound starting weight means 12.5 pounds. That number is achievable within the first 12 weeks of tirzepatide at maintenance doses of 10 or 15 mg weekly [3].